Relyvrio’s Failure Sparks NeuroSense ALS Development Changes

NeuroSense plans to adjust its upcoming clinical trial to avoid the fate of Amylyx’s ALS candidate, which was recently withdrawn from the market due to a lack of efficacy.

neuron-degeneration
NeuroSense is planning a Phase III study for its ALS candidate PrimeC. • Source: Shutterstock

The saga of the ALS treatment Relyvrio may be generating ripple effects across the disease landscape.

Key Takeaways
  • NeuroSense is adjusting its Phase III trial design in part because of Relyvrio's failure.

  • The plan includes having more control of the investigators and...

Alon Ben-Noon, CEO of NeuroSense Therapeutics Ltd., which is developing PrimeC as an amyotrophic lateral sclerosis treatment, said the company is changing its development program in response to the...

More from Clinical Trials

More from R&D